International Journal of Tuberculosis and Lung Disease

Article	Citations
TB infection in adults with diabetes mellitus in Uganda	137
Clinical profile and outcomes of paediatric central nervous system tuberculomas	106
TB-related deaths among adults in Guinea-Bissau	81
Launch of a second wave of IJTLD Clinical Standards for Lung Health	52
Ethambutol-induced optic neuropathy: should we mandate ophthalmic examination in TB treatment?	47
Dr Christopher Zishiri	42
Screening of refugees from Ukraine for TB: a TBnet survey	41
Travel reimbursements, distance to health facility and preventive treatment cascade for drug-resistant TB	41
Decentralising DOT for drug-susceptible TB from the health facilities to the community level in Togo	31
Reply to ‘Estimating TB survival ‐ mind the immortal-time gap’	29
Atorvastatin to reduce bacillary load and attenuate lung damage in TB patients	28
The effect of antenatal isoniazid preventive therapy on birth outcomes in Western Kenya	27
Targeted therapeutic drug monitoring identifies frequent under-dosing of TB drugs	26
Cost-effectiveness of pretomanid-based regimen for highly drug- resistant TB in a low-burden setting	24
Latent TB and depressive symptoms in household contacts of persons with active TB	22
Yield of community outreach events for TB screening	21
CFU counting may underestimate TB bacilli number of blood, biasing limit of detection estimates in spiking experiments	20
The impact of sputum quality on Xpert positivity in active case-finding for TB	18
TB in ageing populations: lessons from Japan and Korea	18
WHO target product profiles for TB preventive treatment	18
Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries	17
Use of a molecular bacterial load assay to distinguish between active TB and post-TB lung disease	17
CAD4TB software updates: different triaging thresholds require caution by users and regulation by authorities	17
Haematological indicators of mortality in people with community-acquired pneumonia living at high altitude	16
The COVID-19 pandemic does not bode well for TB control	16

Are schools prepared to manage students with an asthma attack?	15
Reply to: Observations on malnutrition and anti-TB drugs in Ghana	15
Standards for clinical trials for treating TB	14
Lichenoid drug eruption in patients on anti-TB therapy in a high HIV prevalence setting	14
Assessment of TB patient cost – what about the mitigation strategy?	14
Literature Highlights	14
Advantages and limitations of virtual multi-disciplinary team meetings on difficult-to-treat mycobacteria	14
Introduction of the Simple One-Step stool Xpert Ultra method to detect TB in children and adults	14
Occupational transmission of TB infection during autopsy	13
Assessing patient satisfaction with video-supported therapy for drug-susceptible TB treatment	13
Accessibility and TB patient satisfaction in Nigeria	13
Impact of revised definitions for extensively drug-resistant TB on disease classification	13
Gender differences in health-seeking behaviour, diagnosis and treatment for TB	12
TB disease yield from household contact screening of TB index patients in Pakistan	12
Perceived stigma among people with TB and household contacts	12
A cohort study exploring variables associated with mortality in critically ill TB patients	12
Performance of spirometry assessment at TB diagnosis	12
TB testing in HIV-positive patients prior to antiretroviral treatment	12
Treatment outcomes and safety of bedaquiline, delamanid, and linezolid in multidrug-resistant TB	12
Post-TB lung disease: keep going beyond TB!	11
Prevalence of chronic airflow obstruction in sub-Saharan Africa	11
Factors associated with false-negative for T-SPOT.TB in patients with TB disease	10
Emphasis on post-TB lung disease and other sequelae of TB is good but a public health approach to TB is morally ambitious	10
Population attributable fraction for smoking and diabetes in TB	10
A novel method for contact tracing for TB at household and community level	10
Paediatric TB care in the United Kingdom	10
Initial experience with BPaL-based regimens to treat multidrug-resistant TB	10
Patterns of TB transmission in the United States, 2011–2017	10
Incidence of TB among kidney transplant recipients in a setting with universal isoniazid prophylaxis	10
Updated guidelines for child and adolescent TB	10
Facilitators and barriers to adolescent participation in a TB clinical trial	10
Impact of COVID-19 on extrapulmonary TB and the benefit of decentralised TB services	9
Health status of Italian children living close to cultivations sprayed with pesticides	9
Clinical standards for the diagnosis and management of asthma in low- and middle-income countries	9
Does distance to healthcare facility affect care-seeking for TB-related symptoms in Tanzania?	9
TB case fatality and recurrence in a private sector cohort in Mumbai, India	9
Higher yield using an event-based vs. door-to-door approach for active case-finding for TB	9
Decentralising TB diagnosis and contact management: impact on detection and preventive treatment in children	9
Risk factors for severe COPD exacerbation in Chinese adults	9
Cascade of care for people with TB and diabetes in India	8
Medical management of large and multiple pulmonary echinococcal cysts	8
Perceived stigma related to TB preventive therapy	8
Meeting of two pandemics in prison: a challenging event in a challenging environment	8
Bedaquiline-based all-oral regimen for macrolide-resistant Mycobacterium abscessus pulmonary disease	8
Opportunities to prevent and manage undernutrition to amplify efforts to end TB	8
Post-hospitalisation respiratory and physical functions in patients with SARS-CoV-2 delta	7
Population pharmacokinetics of bedaquiline in patients with drug-resistant TB	7
The effect of systematic screening of the general population on TB case notification rates	7
Community-based intervention and health education to scale up TB preventive treatment for children	7
The household economic burden of drug-susceptible TB diagnosis and treatment in The Gambia	7

Evaluation of QFT-Plus performance using blood samples stored at room temperature	7
Clinical features, microbiology and lung function in post-TB bronchiectasis compared to other aetiologies	7
Mortality and causes of death in non-tuberculous mycobacterial pulmonary disease	7
Proportions of Xpert MTB/RIF Ultra ‘trace’ results vary widely among different populations with presumptive TB	7
Lower TB notification rates in later life in the same birth cohort, Japan, 1950–2020	7
Use of computed tomography for the diagnosis of TB during a paediatric outbreak	7
Protecting healthcare workers from TB	7
Epidemiology, detection, diagnosis and treatment of TB in children in Kazakhstan	7
Cost of TB prevention and treatment in the Philippines in 2017	7
Characteristics, risk factors and outcomes of critically ill patients with active TB	7
A new understanding of clinical patterns in post-TB lung disease	6
TB and chronic pulmonary aspergillosis: a few relevant points	6
Diabetes characteristics and long-term management needs in diabetic TB patients	6
Evaluation of testing face-mask filter samples with LAMP shows high rates of detection in pulmonary TB	6
Estimating TB survival ‐ mind the immortal-time gap	6
TB and COVID-19 co-infection in a pulmonology hospital	6
Impact of COVID-19 on hospitalisations for asthma	6
Rifampicin-resistant TB: discordance between Xpert® MTB/RIF and MTBDRplus results	6
Effect of biological therapies on TB treatment outcomes	6
Clinical experience of TB in patients treated with anti-TNF-α	6
Guidance is needed to mitigate the consequences of analytic errors during antimicrobial susceptibility testing for TB	6
Prevalence and determinants of chronic respiratory diseases in adults in rural Sudan	6
Extemporaneously compounded liquid formulations of clofazimine	6
Bronchiectasis exacerbations: certainties and future challenges	6
Cutaneous adverse drug reactions to fixed-dose combination treatments for TB	6
Population attributable fraction for undernutrition due to TB does not take account of bidirectional causality	6
Time to integrate epidemiological and economic models for TB	6
Mycobacterium tuberculosis genotypes isolated from clinical specimens of extrapulmonary TB	6
A scoping review of interventions to mitigate common non-communicable diseases among people with TB	6
Predictors of TB disease in HIV-exposed children from Southern Africa	6
TB prevalence among pregnant women with HIV in Rio de Janeiro, Brazil	6
Contribution of Xpert® MTB/RIF to pediatric TB diagnosis in Mozambique	6
TB therapeutic drug monitoring – analysis of opportunities in Romania and Ukraine	6
Supplementary inspired oxygen fraction is a simple clinical tool that predicts clinical deterioration	6
Rapid molecular diagnostics to detect resistance to second-line anti-TB drugs	6
Urine LAM diagnostics can close the deadly testing gap for TB	6
The high costs facing TB-affected households in Mali	6
Exhaled breath specimens subjected to point-of-care lipoarabinomannan testing	6
TB disease in children from the prehistoric era	6
If you want to go far, go together: standardisation and data sharing in TB drug development	6
Paediatric formulations for the treatment of drug resistant TB: closing the gaps	6
TB notifications among citizens and non-citizens in Taiwan	6
Financial impact of COVID-19 on TB patients in India	6
New diagnostics for the spectrum of asymptomatic TB: from infection to subclinical disease	5
Quality assessment of clinical practice guidelines for the management of wheezing disorders in children	5
Literature Highlights	5
Lessons learned from treating drug-resistant TB and how to apply these to drug-susceptible TB	5
The rise of artificial intelligence reading of chest X-rays for enhanced TB diagnosis and elimination	5
A study of persistent symptoms and pulmonary function at 3 months post moderate or severe COVID-19 in Angola	5
Implementation of modified, all-oral shorter TB regimens in Armenia	5
Responding to the post-pandemic crisis: post-exposure prophylaxis for TB	5
A systematic review on the effect of diabetes mellitus on the pharmacokinetics of TB drugs	5
National approaches to TB care in adolescents	5
High prevalence of multidrug-resistant TB among household contacts in a high burden setting	5
After DOT, the brave new world?	5
Approaches and processes for paediatric chest X-ray classification used in the SHINE TB treatment-shortening trial	5
Metabolic characterisation of adult Ugandan patients with TB and diabetes mellitus comorbidity	5
Family directly observed therapy for children with drug-resistant TB	5
An epidemiological analysis of TB trends in native and migrant populations, New Mexico, 1993–2021	5
TB screening of Ukrainian refugees in Germany	5
Fluoroquinolone preventive therapy for children exposed to MDR-TB	5
Use of stool swabs in molecular transport media increases access to Xpert Ultra testing for TB in children	5
WHO drug-resistant TB guidelines 2022: what is new?	5
Determinants of treatment outcomes in patients with multidrug-resistant TB	5
Early line-probe assay using DNA specimens in patients with pulmonary TB	5
Evidence and ethical considerations for the treatment of contacts exposed to drug-resistant TB	5
Geographical differences in chronic obstructive pulmonary disease mortality trends by sex, Spain, 1980–2021	5
Factors associated with presenting to private sector care providers at the onset of TB symptoms	5
A bold new future for the IJTLD	5
TB mortality in low-incidence countries: can we reduce it further?	5
Glutathione and N-acetylcysteine in TB management	5
Sputum pooling for rapid and cost-effective active case-finding for TB in prisons	5
TB screening, prevention and treatment cascade in a Malawi prison	4
Prevalence of and risk factors for depressive symptoms in non-tuberculous mycobacterial pulmonary disease	4
National survey on the impact of the war in Ukraine on TB diagnostics and treatment services in 2022	4
First report of multidrug-resistant M. tuberculosis Beijing strain isolated from the indigenous population in Tunisia	4
Risk factors for the isolation of Haemophilus influenzae in patients with stable chronic obstructive pulmonary disease	4
Evaluation of the MolecuTech® REBA MTB-XMDR kit for detection of pre-extensively drug-resistant TB	4
Concomitant pulmonary disease is common among patients with extrapulmonary TB	4
Bridging the gap: key evidence needed to strengthen global policies to end TB	4

Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications	4
Use of rapid molecular TB diagnostics for incarcerated people in Brazil	4
Establishing proof of concept for utility of Trueprep®-extracted DNA in line-probe assay testing	4
Early mortality during rifampicin-resistant TB treatment	4
Factors associated with patient delay in the diagnosis of TB – a study of health-seeking behaviour	4
Diabetes mellitus and TB – finding strategies to reduce the double burden of disease	4
Eosinophils in bronchiectasis: searching for a new endotype	4
Attrition in the treatment cascade among elderly patients with multidrug-resistant TB	4
Factors associated with referrals for directly observed treatment and unsuccessful treatment	4
A comprehensive person-centred TB care model, from malnutrition to mental health	4
Efflux pump gene expression study using RNA-seq in multidrug-resistant TB	4
Launch of the IJTLD Clinical Standards for Lung Health	4
Impact of the COVID-19 pandemic on TB infection testing	4
TB screening of children from Ukraine in Germany	4
Potential use of nasopharyngeal aspirate for pediatric TB diagnosis	4
Stool-based Xpert testing for diagnosis of TB in children and critically ill adults	4
Impact of Rv0678 mutations on patients with drug-resistant TB treated with bedaquiline	4
SMaRT-PCR: sampling using masks and RT-PCR, a non-invasive diagnostic tool for paediatric pulmonary TB	4
Programmatic implications of a sub-national TB prevalence survey in India	4
Clinical outcomes in comorbid COVID-19 and TB cases	4
Is it time for new fixed-dose combinations and revised weight bands for children with drug-susceptible TB?	4
Interventions to enhance treatment adherence and retention in care for HIV-TB	4
Impact of COVID-19 on diagnosis and testing for TB in a high-resource, low-burden setting	3
TB and interstitial lung disease: a systematic review and meta-analysis	3
Identifying gaps in the cascade of care for latent TB infection in a low-incidence setting	3
Characterising cause of death among people treated for drug-susceptible TB in India	3
Contribution of post-infectious bronchiolitis obliterans to non-cystic fibrosis bronchiectasis in children	3
Isolation and purification of lipoarabinomannan from urine of adults with active TB	3
Borderline T-SPOT.TB results: test reliability, patient characteristics, and TB progression	3
Successful rechallenge of rifabutin in rifampicin-induced thrombocytopenia during TB treatment	3
Factors associated with screening failure and study withdrawal in multidrug-resistant TB	3
The effect of TB patient delay on loss to follow-up in Portugal	3
Risk factors in ICU patients with initial acquisition of carbapenemase-resistant Klebsiella Pneumoniae	3
Post-TB bronchiectasis: clinical characteristics and microbiology	3
Reply to: “TB and chronic pulmonary aspergillosis: a few relevant points”	3
Ukraine embraces innovation in its fight against another deadly foe: TB	3
Stable, compounded bedaquiline suspensions to support practical implementation of pediatric dosing in the field	3
Increasing trend of non-tuberculous mycobacteria in a Croatian hospital, 2012–2019	3
The economic burden of TB-affected households in DR Congo	3
Prevalence, temporal trends and risk factors of drug-resistant TB in Zibo, China, 2018–2021	3
Outcomes of childhood TB in countries with a universal BCG vaccination policy	3
Culture-negative TB: clinical characteristics, risk factors and treatment outcomes	3
Work-related interstitial lung diseases: reassessing the burden	3
Outcomes of TB contact tracing and predictors of success: a 10-year retrospective cohort analysis in Birmingham, UK	3
Outcomes for people with TB by disease severity at presentation	3
The interplay between TB and lung cancer: risk, prognosis and treatment dynamics	3
The urgent need to improve on low implementation rates for TB preventive treatment for people living with HIV	3
Household air pollution and COPD: cause and effect or confounding by other aspects of poverty?	3
Therapeutic drug monitoring for isoniazid and rifampicin exposure	3
Preventive treatment for MDR-TB exposure in households	3
Towards meaningful inclusion of people affected by TB: lessons from the COVID-19 response	3
Adverse events among persons with TB using in-person vs. electronic directly observed therapy	3
Long-term follow-up of persons diagnosed with multidrug-resistant TB in Chennai, India, 2013–2020	3
Electronic nicotine delivery system use among current smokers in India	3
Artificial intelligence for TB education and counselling: a modified Delphi consensus	3
TB in the elderly: clinical features and outcomes	3
Time to care-seeking for TB symptoms	3
Ocular TB in Western Australia	3
Highlighting the characteristics of TB disease in older people	3
Conjugated hyperbilirubinemia associated with accidental rifapentine overdose	3
Predictive value of neutrophil-to-lymphocyte ratio in severe pulmonary infection: sex-specific cut-off values needed	3
The scientific response to TB – the other deadly global health emergency	3
Introduction of new drugs for drug-resistant TB in Iraq	3
Chronic respiratory disease in adult outpatients in three African countries: a cross-sectional study	3
Prevalence and determinants of chronic respiratory diseases in adults in Sudan	3
Poor dietary intake at hospital admission is a predictor of mortality in patients with COVID-19	3
Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda	3
A comparison of bronchoalveolar lavage and gastric aspirate for diagnosis of paediatric TB	3